

Product datasheet for **AP55755PU-S**

FLT3 pTyr842 Rabbit Polyclonal Antibody

Product data:

Product Type:	Primary Antibodies
Applications:	WB
Recommended Dilution:	Western blot: 1:500~1:1000.
Reactivity:	Human, Mouse
Host:	Rabbit
Clonality:	Polyclonal
Immunogen:	Peptide sequence around phosphorylation site of tyrosine 842(S-N-Y(p)-V-V) derived from Human FLT3 (KLH-conjugated)
Specificity:	The antibody detects endogenous levels of FLT3 only when phosphorylated at tyrosine 842.
Formulation:	Rabbit IgG in phosphate buffered saline (without Mg ²⁺ and Ca ²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol State: Aff - Purified State: Liquid Ig fraction
Concentration:	lot specific
Purification:	Affinity chromatography using epitope-specific peptide
Conjugation:	Unconjugated
Storage:	Upon receipt, store undiluted (in aliquots) at -20°C. Avoid repeated freezing and thawing.
Stability:	Shelf life: one year from despatch.
Predicted Protein Size:	170 kDa
Gene Name:	fms related tyrosine kinase 3
Database Link:	Entrez Gene 2322 Human P36888




[View online »](#)

Background:

FLT3 encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.

Synonyms:

FL cytokine receptor, STK1

Product images:


Western blot analysis of extracts from HepG2 cells treated with EGF using FLT3 (Phospho-Tyr842) Antibody. The lane on the right is treated with the antigen-specific peptide.